JP6580791B2 - 調節t細胞媒介性疾患の予防または治療用薬学的組成物 - Google Patents
調節t細胞媒介性疾患の予防または治療用薬学的組成物 Download PDFInfo
- Publication number
- JP6580791B2 JP6580791B2 JP2018535058A JP2018535058A JP6580791B2 JP 6580791 B2 JP6580791 B2 JP 6580791B2 JP 2018535058 A JP2018535058 A JP 2018535058A JP 2018535058 A JP2018535058 A JP 2018535058A JP 6580791 B2 JP6580791 B2 JP 6580791B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- icosl
- hcmsc
- cell
- regulatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003289 regulatory T cell Anatomy 0.000 title claims description 62
- 238000011282 treatment Methods 0.000 title claims description 51
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 15
- 230000002265 prevention Effects 0.000 title claims description 10
- 230000001404 mediated effect Effects 0.000 title description 36
- 201000010099 disease Diseases 0.000 title description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 33
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 120
- 230000014509 gene expression Effects 0.000 claims description 83
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 59
- 230000006698 induction Effects 0.000 claims description 55
- 230000004069 differentiation Effects 0.000 claims description 38
- 230000001939 inductive effect Effects 0.000 claims description 33
- 210000004027 cell Anatomy 0.000 claims description 31
- 239000002158 endotoxin Substances 0.000 claims description 28
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 28
- 230000035755 proliferation Effects 0.000 claims description 21
- 208000023275 Autoimmune disease Diseases 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 18
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims description 18
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 18
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 18
- 206010009887 colitis Diseases 0.000 claims description 18
- 210000000130 stem cell Anatomy 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 108010002352 Interleukin-1 Proteins 0.000 claims description 15
- 208000027866 inflammatory disease Diseases 0.000 claims description 15
- 102100034980 ICOS ligand Human genes 0.000 claims description 13
- 108010002350 Interleukin-2 Proteins 0.000 claims description 10
- 230000002018 overexpression Effects 0.000 claims description 9
- 108090001005 Interleukin-6 Proteins 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 6
- 210000001185 bone marrow Anatomy 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 4
- 208000009137 Behcet syndrome Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 4
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
- 208000004631 alopecia areata Diseases 0.000 claims description 4
- 208000002399 aphthous stomatitis Diseases 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 201000001981 dermatomyositis Diseases 0.000 claims description 3
- 230000019491 signal transduction Effects 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 208000033116 Asbestos intoxication Diseases 0.000 claims description 2
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 208000026019 Fanconi renotubular syndrome Diseases 0.000 claims description 2
- 201000006328 Fanconi syndrome Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 2
- 206010020850 Hyperthyroidism Diseases 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 241000721454 Pemphigus Species 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010065159 Polychondritis Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 201000010001 Silicosis Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 2
- 206010043781 Thyroiditis chronic Diseases 0.000 claims description 2
- 208000018839 Wilson disease Diseases 0.000 claims description 2
- 208000010638 acquired aplastic anemia Diseases 0.000 claims description 2
- 206010003441 asbestosis Diseases 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 201000002491 encephalomyelitis Diseases 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 208000009169 relapsing polychondritis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 206010043207 temporal arteritis Diseases 0.000 claims description 2
- 108091007960 PI3Ks Proteins 0.000 claims 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 2
- 230000005784 autoimmunity Effects 0.000 claims 2
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 1
- 208000019802 Sexually transmitted disease Diseases 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 38
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 38
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 38
- 238000000684 flow cytometry Methods 0.000 description 27
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 27
- 230000001965 increasing effect Effects 0.000 description 25
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 238000003501 co-culture Methods 0.000 description 17
- 238000012790 confirmation Methods 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 17
- 108020004999 messenger RNA Proteins 0.000 description 15
- 230000008859 change Effects 0.000 description 14
- 239000003446 ligand Substances 0.000 description 13
- 102000000589 Interleukin-1 Human genes 0.000 description 12
- 238000011529 RT qPCR Methods 0.000 description 12
- 230000007730 Akt signaling Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000003472 neutralizing effect Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 230000006870 function Effects 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 238000003197 gene knockdown Methods 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 108091027967 Small hairpin RNA Proteins 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 230000031261 interleukin-10 production Effects 0.000 description 7
- 230000037452 priming Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000004055 small Interfering RNA Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- KGPGFQWBCSZGEL-ZDUSSCGKSA-N GSK690693 Chemical compound C=12N(CC)C(C=3C(=NON=3)N)=NC2=C(C#CC(C)(C)O)N=CC=1OC[C@H]1CCCNC1 KGPGFQWBCSZGEL-ZDUSSCGKSA-N 0.000 description 6
- 230000001464 adherent effect Effects 0.000 description 6
- 230000001506 immunosuppresive effect Effects 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 241000713666 Lentivirus Species 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 108010004469 allophycocyanin Proteins 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 102000046492 human ICOSLG Human genes 0.000 description 5
- 210000002602 induced regulatory T cell Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 5
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 229940126638 Akt inhibitor Drugs 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- -1 and pollen Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229940041476 lactose 100 mg Drugs 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 238000010232 migration assay Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000003197 protein kinase B inhibitor Substances 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 101710093458 ICOS ligand Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- CSTRPYAGFNTOEQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;octadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O CSTRPYAGFNTOEQ-MGMRMFRLSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- QAQJMLQRFWZOBN-UHFFFAOYSA-N 2-(3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl)-2-hydroxyethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)C1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001042104 Homo sapiens Inducible T-cell costimulator Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101150016644 ICOSLG gene Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100021317 Inducible T-cell costimulator Human genes 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101001042093 Mus musculus ICOS ligand Proteins 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000012162 RNA isolation reagent Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N gallic acid propyl ester Natural products CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229940079826 hydrogen sulfite Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000027405 negative regulation of phosphorylation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
従って、本発明のICOSLは、間葉系幹細胞表面に発現された形態またはそれを組み換えて合成された分離形態を全て制限なく含むことができる。
ヒト骨髄を健常な男性志願者から得て、仁荷大学校病院の倫理委員会の承認(IRB #10−51)によって実験を遂行した。hcMSCを以前の文献(Song SU,et al.(2008),Variations of clonal marrow stem cell lines established from human bone marrow in surface epitopes,differentiation potential,gene expression,and cytokine secretion.Stem cells and development 17(3):451−461.)による層分離培養法で分離した。全てのhcMSCを10%FBSと1%ペニシリン/ストレプトマイシンが補充された低グルコースDMEM培地で培養し、分離されたhcMSCに対するフローサイトメトリーを通して様々な細胞表面マーカーを確認した。前記分析に用いられた抗体は、次のとおりである:抗−CD29(Serotec,Kidlington,UK)、抗−CD44(Serotec)、抗−CD105(Serotec)、抗−CD34(BD Biosciences,San Diego,CA,USA)、抗−CD45(BD Biosciences)、抗−CD90(BD Biosciences)、抗−CD73(BD Biosciences)、抗−HLA class I(BD Biosciences)、抗−HLA DR(BD Biosciences)、抗−CD80(eBiosciences,San Diego,CA,USA)、抗−CD86(SouthernBiotech,Birmingham,AL,USA)、および抗−Oct4(Cell Signaling Technology,Danvers,MA,USA)。細胞は、フローサイトメーター(FACS Calibur;BD Biosciences)を利用して分析し、同型でマッチされた対照群抗体(Isotype matched control antibody)を対照群として利用した。フローサイトメトリーを利用してhcMSCの表面マーカー発現を確認した結果を図1に示した。
hcMSCとPHAで処理されたPBMCを共同培養し、より具体的には、1X106PBMCを1uM CFSEで染色し、染色されたPBMCを1X105または1X106のhcMSCの存在または非存在下で1ug/mlのPHAで刺激した。PHA刺激72時間後、PBMCを収穫してフローサイトメーターで分析し、その結果を図2に示した。
PBMC(Peripheral blood mononuclear cell)を健常な供与者から得て、ficoll−hypaque密度勾配遠心分離を通して分離した。PBMCからCD4+T細胞をCD4+ T cell Isolation Kit MicroBeads(Miltenyi Biotech,Bisley,Surrey,UK)を利用して収得した。
hcMSCとCD4+T細胞を共同培養し、これらの細胞の様子を光学顕微鏡(X400)で確認し、存在形態によって付着または浮遊形態に分けてこれらのCD25およびFoxP3発現量をフローサイトメトリー法を通して比較した。
hcMSCとT細胞の直接的な相互作用がTreg分化を誘導するということを確認したので、hcMSC上のICOSLの発現が信号伝達に重要な役割を果たすと予想し、それを確認するための実験を遂行した。Treg誘導条件下でhcMSCとCD4+Tregを2日間共同培養し、hcMSCでのICOSLタンパク質の発現をフローサイトメトリーで、mRNAの発現を共同培養24時間後qRT−PCRを通して確認し、hcMSC上のICOSLの発現を非付着CD4+T細胞を除去した後、免疫蛍光染色を通して共焦点顕微鏡を通して確認した。hcMSCの総RNAは、EasyBlue RNA isolation reagent(Intron,Biotechnology,Sungnam,Korea)利用して測定し、cDNAを2ugの総RNAから合成した。
RT−PCRをAccuPower PCR premix(Bioneer)を通して遂行した。増幅されたPCR産物をSybrSafeを含む1%アガロースゲル上に電気泳動し、蛍光イメージ分析器を通して分析した。PCRは、下記プライマーを利用して遂行した:IL−10(正方向5´−ATCCAAGACAACACTACTAA−3´および逆方向5´−TAAATATCCTCAAAGTTCC−3´)、IL−1(正方向5´−GCTGAGTGCTGCAAAGTACC−3´および逆方向5´−TGAGGAGGGA−CTTGTGACTG−3´)、IL−1R(正方向5´−ATTGATGTTCGTCCCTGT CC−3´および逆方向5´−CCTCCACCTTAGCAGGAACA−3´)とGAPDH(正方向5´−CCACTGGCGTCTTCACCAC−3´および逆方向5´−CCTGCTTCACCACCTTCTTG−3´)。
T細胞活性化の間、T細胞のICOSは上向き調節されているものと知られており、APCのICOSLの発現は、Treg誘導促進を通してT細胞の反応を抑制できるものと知られている。hcMSCがT細胞のICOS発現に影響を与えるか否かを確認するために、hcMSCとCD4+T細胞をTreg分化条件下で48時間の間共同培養し、hcMSCの存在下でCD4+T細胞のICOSの誘導を5回の独立的実験を通して確認した結果を図7に示した。
Treg誘導とhcMSC上のICOSLとの相互作用を直接的に検証するために、ICOSLの機能を遮断し、それによる変化を確認した。ICOSLの機能遮断のために、ICOSLに対する中和抗体処理実験および遺伝子ターゲティング実験を遂行した。
7.1.ICOSL過発現誘導確認
MSC媒介Treg誘導において、hcMSCでICOSLの過発現を誘導し、それによる効果を確認した。ICOSの過発現のために、全長ヒトICOSL遺伝子を発現するレンチウイルスをhcMSCにウイルスパッキング構造体(viral packaging contructs)と共に導入した。より具体的には、全長ヒトICOSL遺伝子発現ベクターをC−terminal mGFPタギングされたpLentiベクターにサブクローンした。cDNA定量化のために、これをcompetent E.coli細胞に形質転換させ、結果物であるクローンをICOSL挿入確認のために配列分析した。293FT細胞にICOSL発現ベクターをLenti−vpak packaging kit(Origene)を利用して形質感染させた。2.5×106の293FT細胞をレンチウイルス生産のために100−mm培養ディッシュに分注した。2日後、ウイルス−包含培養上澄みを収穫し、hcMSC感染に使用した。hcMSCs感染後、qRT−PCR、ウェスタンブロット、フローサイトメトリーをICOSL過発現水準確認のために遂行し、その結果を図10に示した。
前記7.1.でhcMSCでICOSLが過発現されたことを確認したので、hcMSCICOSLでのTreg誘導が増加したか否かをフローサイトメトリーおよびELISAを通して確認し、その結果を図11に示した。
図11に示したように、hcMSCICOSLは、空ベクターが導入された対照群と比較してさらに多くのCD25+FoxP3+Tregを誘導し、hcMSCICOSLにより誘導されたTregはさらに多くのICOSを発現した(A)。また、hcMSCICOSLは、Tregによるエフェクター抗炎症性サイトカインであるIL−10の生産および分泌をさらに促進することをフローサイトメトリーおよびELISA分析を通して確認した。このような結果は、ICOSLがMSC−媒介Treg誘導に非常に重要な役割を果たすことを示すものであり、これは、MSCのICOSLが効果的なTreg誘導剤としての役割を果たすということを示す結果である。
hcMSCがTreg誘導条件下でCD4+T細胞がCD25、FoxP3、ICOSおよびIL−10を発現するTreg表現型を示すように誘導できることを確認した。一方、Tregは、in vitroおよびin vivoのいずれでもリンパ球抑制活性を有しているということが知られているので、活性化されたリンパ球の増殖をTregが抑制できるか否かを確認した。
一方、hcMSCICOSL−誘導されたTregおよびhcMSCEmp−誘導されたTregの間にPBMC抑制に対する明確な機能的差は現れなかった。
PI3K−Akt信号伝達経路は、T細胞の増殖、移動、分化およびサイトカイン生産のようなT細胞の機能に重要な役割を果たすものと知られている。ICOSLの生理学的な機能をさらに確認するために、Treg分化の間のICOSL−ICOS相互作用による分子信号調節を信号伝達の観点から確認した。
ICOSL媒介されたTreg分化において、PI3K−Akt信号経路が関与するか否かを追加確認するために、PI3K(phosphatidylinositide 3−kinases)抑制剤LY294002またはAkt抑制剤GSK690693を処理し、それによる結果を確認した。Akt抑制剤GSK690693(Calbiochem,San Diego,CA,USA)は、1uM濃度で、LY294002(Cell Signaling Technology,Danvers,MA,USA)は、5−10uM濃度で使用した。
また、rhICOSL−誘導されたTreg誘導においてPI3K−Akt抑制の影響をLY294002(5μM)またはGSK690693(1μM)を2日間処理した後、rhICOSL−処理されたCD4+T細胞の培養を通したCD25、ICOS、FoxP3の発現を通して分析し、その結果を図14に示した。
異なるMSCクローンは、互いに異なる機能的特性を示すものと知られているので、hcMSCによってヒトTregを誘導するためのICOSL発現程度が異なるか否かを確認した。計6個のhMSC株を利用し、一つの授与者由来の5個のクローナルhcMSC(hcMSC1−5)および一つの非−クローナルhcMSC(hncMSC)でICOSLの基本発現をウェスタンブロットおよびqRT−PCRを通して確認した。また、hcMSCのTreg誘導活性を確認するために、hcMSC1およびhcMSC4細胞株のTreg誘導能力を混合リンパ球反応(mixed lymphocyte reaction、MLR)でPBMCとの共同培養またはTreg誘導条件でhncMSC、hcMSC1およびhcMSC4でCD25、FoxP3の発現比較を通して確認した。その結果を図15に示した。
MSCの免疫抑制活性は、様々なプライミングおよび適切な刺激により左右できることが知られている。hcMSCでのICOSLの発現がTreg誘導と関連があるものと確認したので、ICOSLの発現を増加させる場合、さらに多くのTregが増加し、hcMSCの免疫抑制機能が強化できるものと予想した。これを確認するために、ICOSLの発現を誘導できる前炎症性サイトカインを確認するための実験を先に遂行した。先ず、適切なプライミング因子を見つけるために、IL−1β(10ng/mL)、TNF−α(10ng/mL)、LPS(2μg/mL)をそれぞれ24時間の間hcMSCに処理した後、qRT−PCRを通して、ICOSLの発現を1時間、3時間後に確認した。また、IL−1β処理によってhcMSCでのIL−1Rの発現が変化するか否かを確認するために、IL−1βを24時間の間処理した後、hcMSCでのIL−1Rの発現を共に確認し、その結果を図16に示した。
hncMSCと比較してhcMSC4がICOSLの発現誘導効果にさらに優れているという事実を確認したので、IL−1β処理によるクローナル(clonal)および非−クローナルMSCのICOSL誘導効果差を確認するための実験を遂行した。具体的には、24時間の間IL−1β(10ng/ml)でhncMSCおよびhcMSC4を処理し、qRT−PCRを通してICOSLのmRNA発現を時間によって分析し、ウェスタンブロットおよびフローサイトメトリーを通してICOSLのタンパク質発現変化を確認した。フローサイトメトリーは、5回の独立実験の代表値で示し、その結果は、図17に示した。
IL−1βでプライミングされたhcMSCがTreg誘導活性をさらに増加させることができるか否かを検証するために、hcMSCをIL−1βで24時間の間処理して得られたhcMSCIL−1βをTreg分化条件下でCD4+T細胞と2日間共同培養し、これによるCD4+CD25+FoxP3+またはCD4+ICOS+Foxp3+T細胞集団の比率をフローサイトメトリーを通して確認した。また、抗−ICOSL中和抗体(5ug/ml)を処理した後、hcMSCIL−1βとCD4+T細胞を共同培養し、ICOSの中和抑制がIL−1βプライムされたhcMSCによるTreg誘導を抑制できるか否かを確認し、その結果を図19に示した。
15.1.DDS大腸炎誘導動物モデルの製造および実験方法
前記実施例を通してhcMSCの免疫抑制能力において、ヒトICOSLの機能的役割を確認したので、実際、このような処理がT細胞媒介疾患の治療に効果を奏することができるか否かを確認するために、T細胞媒介疾患の一つである大腸炎モデルでMSC投与による免疫抑制効果に及ぼす影響を確認した。
DDS誘導された大腸炎マウスモデルで大腸炎深刻度を毎日確認し、糞便の濃度、血液有無、体重が減少したか否かでこれを評価した。マウスから全体大腸を除去し、大腸の長さを間接的炎症マーカーで確認した。大腸内マウスTregの分析のために、mesentericリンパ節から分離された細胞をAPC−接合された抗−CD25、FITC−接合された抗−CD4、およびPE−接合された抗−FoxP3抗体(eBioscience)と共に培養した。In vitro実験のために、CD4+T細胞を脾臓およびリンパ節から分離し、分離された細胞の純度をフローサイトメトリーを通して確認した。
CD4+T細胞は、1ug/mlのプレート付きの抗−CD3 mAbおよび3μg/mLのsoluble抗−CD28 mAbで活性化させ、1日および2日目に分析を遂行し、その結果を図21に示した。
1.1 散剤の製造
ICOSL 100mg
ラクトース 100mg
タルク 10mg
前記の成分を混合し、気密包に充填して散剤を製造する。
ICOSL 100mg
トウモロコシデンプン 100mg
ラクトース 100mg
ステアリン酸マグネシウム 2mg
前記の成分を混合した後、通常の錠剤の製造方法に従って打錠し、錠剤を製造する。
ICOSL 100mg
トウモロコシデンプン 100mg
ラクトース 100mg
ステアリン酸マグネシウム 2mg
通常のカプセル剤の製造方法に従って前記の成分を混合し、ゼラチンカプセルに充填して錠剤を製造する。
ICOSL 100mg
注射用滅菌蒸留水 適量
pH調節剤 適量
通常の注射剤の製造方法に従って1アンプル当たり(2ml)前記の成分含量で製造する。
ICOSL 100mg
砂糖 20g
異性化糖 20g
レモン香 適量
精製水を加えて全体1,00mlに合わせた。通常の液剤の製造方法に従って前記の成分を混合した後、茶色瓶に充填し、滅菌させて液剤を製造する。
Claims (15)
- ICOSL過発現間葉系幹細胞を含む、炎症性疾患または自己免疫性疾患の予防または治療用薬学的組成物。
- 前記ICOSLが、間葉系幹細胞の表面に発現されることを特徴とする、請求項1に記載の炎症性疾患または自己免疫性疾患の予防または治療用薬学的組成物。
- 前記幹細胞が、クローナル幹細胞であることを特徴とする、請求項1に記載の炎症性疾患または自己免疫性疾患の予防または治療用薬学的組成物。
- 前記幹細胞が、骨髄由来間葉系幹細胞であることを特徴とする、請求項1に記載の炎症性疾患または自己免疫性疾患の予防または治療用薬学的組成物。
- 前記ICOSLが、T細胞のICOS(Induced T cell co−stimulator)発現を増加させることを特徴とする、請求項1に記載の炎症性疾患または自己免疫性疾患の予防または治療用薬学的組成物。
- 前記ICOSLが、PI3K(phosophoinositide 3−kinase)−Akt信号経路を活性化させることを特徴とする、請求項1に記載の炎症性疾患または自己免疫性疾患の予防または治療用薬学的組成物。
- 前記間葉系幹細胞が、IL−1β、TNF−α、IL−6、IL−2、IL−1およびLPS(lipopolysaccharide)からなる群から選択された1種以上で処理されたことを特徴とする、請求項1に記載の炎症性疾患または自己免疫性疾患の予防または治療用薬学的組成物。
- 前記T細胞のICOSの発現の増加が、ICOSL過発現した間葉系幹細胞とT細胞の接触によって誘導されることを特徴とする、請求項5に記載の炎症性疾患または自己免疫性疾患の予防または治療用薬学的組成物。
- 前記炎症性疾患が、狼瘡、シェーグレン症候群、リウマチ関節炎、線維筋炎、強皮症、強直性脊椎炎、ベーチェット病、アフタ性口内炎、ギラン・バレー症候群、円形脱毛症、皮膚筋炎、クローン病、大腸炎、結節性多発動脈炎、再発性多発軟骨炎および自己免疫血小板減少症で構成された群から選択された1種以上であることを特徴とする、請求項1に記載の炎症性疾患または自己免疫性疾患の予防または治療用薬学的組成物。
- 前記自己免疫性疾患が、リウマチ性関節炎、全身性強皮症、膵臓細胞抗体によるインスリン依存型小児期糖尿病、円形脱毛症、乾癬、天疱瘡、喘息、アフタ性口内炎、慢性甲状腺炎、一部の後天性再生不良性貧血、原発性胆汁性肝硬変、潰瘍性大腸炎、ベーチェット病、クローン病、珪肺、石綿肺症、IgA腎臓疾患、レンサ球菌感染後糸球体腎炎、シェーグレン症候群、ギラン・バレー症候群、皮膚筋炎、多発性筋炎、多発性硬化症、自己免疫性溶血性貧血、自己免疫性脳脊髄炎、重症筋無力症、グレーブス甲状腺亢進症、結節性多発性動脈炎、強直性脊椎炎、線維組織炎、側頭動脈炎、ウィルソン病、ファンコーニ症候群、多発性骨髄腫および全身性エリテマトーデスからなる群から選択された1種以上であることを特徴とする、請求項1に記載の炎症性疾患または自己免疫性疾患の予防または治療用薬学的組成物。
- ICOSL過発現間葉系幹細胞を含む、CD4+T細胞の調節T細胞への分化および分化誘導された調節T細胞の増殖誘導用組成物。
- IL−1β、TNF−α、IL−6、IL−2、IL−1およびLPS(lipopolysaccharide)からなる群から選択された1種以上を含むことを特徴とする、請求項11に記載のCD4+T細胞の調節T細胞への分化および分化誘導された調節T細胞の増殖誘導用組成物。
- ICOSL過発現間葉系幹細胞によりin vitroにおいてCD4+T細胞を処理するステップを含む、CD4+T細胞の調節T細胞への分化および分化誘導された調節T細胞の増殖を誘導する方法。
- 前記ICOSL過発現間葉系幹細胞が、IL−1β、TNF−α、IL−6、IL−2、IL−1およびLPS(lipopolysaccharide)からなる群から選択された1種以上で前処理されたことを特徴とする、請求項13に記載のCD4+T細胞の調節T細胞への分化および分化誘導された調節T細胞の増殖を誘導する方法。
- 前記処理が、ICOSL過発現間葉系幹細胞をCD4+T細胞に接触させることである、請求項13に記載のCD4+T細胞の調節T細胞への分化および分化誘導された調節T細胞の増殖を誘導する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0023551 | 2016-02-26 | ||
KR20160023551 | 2016-02-26 | ||
PCT/KR2017/002096 WO2017146538A1 (ko) | 2016-02-26 | 2017-02-24 | 조절 t 세포 매개성 질환의 예방 또는 치료용 약학적 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019501183A JP2019501183A (ja) | 2019-01-17 |
JP6580791B2 true JP6580791B2 (ja) | 2019-09-25 |
Family
ID=59685776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018535058A Active JP6580791B2 (ja) | 2016-02-26 | 2017-02-24 | 調節t細胞媒介性疾患の予防または治療用薬学的組成物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US11096967B2 (ja) |
EP (1) | EP3388514B1 (ja) |
JP (1) | JP6580791B2 (ja) |
KR (1) | KR102025417B1 (ja) |
CN (1) | CN108699524B (ja) |
AU (1) | AU2017224499B2 (ja) |
RU (1) | RU2727900C2 (ja) |
SG (2) | SG11201805468RA (ja) |
WO (1) | WO2017146538A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11058729B2 (en) | 2018-01-25 | 2021-07-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Exosomes and miRNA to treat glaucoma |
CN111454888A (zh) * | 2019-01-18 | 2020-07-28 | 天津市第一中心医院 | 一种干细胞处理方法及使用该方法得到的细胞和应用 |
KR102268242B1 (ko) * | 2020-01-06 | 2021-06-23 | 에스씨엠생명과학 주식회사 | 줄기세포의 기능강화용 조성물 |
CN111481573A (zh) * | 2020-03-26 | 2020-08-04 | 卡替(上海)生物技术股份有限公司 | 牙髓间充质干细胞在制备克罗恩病治疗药物中的用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6521749B1 (en) * | 1999-09-21 | 2003-02-18 | Genetics Institute, Inc. | GL50 nucleic acids and uses therefor |
US8318905B2 (en) * | 2004-04-23 | 2012-11-27 | Richard Kroczek | Antibodies for depletion of ICOS-positive cells in vivo |
WO2006003999A1 (ja) * | 2004-07-05 | 2006-01-12 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | ヒト抗ヒトb7rp-1抗体およびその抗体フラグメント |
CN101426533A (zh) * | 2005-12-08 | 2009-05-06 | 路易斯维尔大学研究基金会有限公司 | 免疫刺激组合物和方法 |
WO2009050282A1 (en) * | 2007-10-17 | 2009-04-23 | Txcell | Tr1 cells, mesenchymal stem cells and uses thereof |
RU2540018C2 (ru) * | 2008-03-13 | 2015-01-27 | Биотест Аг | Средство для лечения заболевания |
US8709417B2 (en) * | 2009-09-30 | 2014-04-29 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
ES2724451T3 (es) * | 2010-02-04 | 2019-09-11 | Univ Pennsylvania | ICOS regula fundamentalmente la expansión y la función de linfocitos Th17 humanos inflamatorios |
WO2013161408A1 (ja) * | 2012-04-26 | 2013-10-31 | 国立大学法人京都大学 | T細胞の分化誘導方法、t細胞の製造方法、t細胞、医薬組成物、及び、スクリーニング方法 |
ES2434853B1 (es) * | 2012-06-12 | 2014-09-30 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos |
WO2015088414A1 (en) * | 2013-12-13 | 2015-06-18 | Isletone Ab | Immunomodulatory compositions |
EP3546567A1 (en) * | 2014-12-06 | 2019-10-02 | GEMoaB Monoclonals GmbH | Genetic modified pluri- or multipotent stem cells and uses thereof |
-
2017
- 2017-02-24 SG SG11201805468RA patent/SG11201805468RA/en unknown
- 2017-02-24 JP JP2018535058A patent/JP6580791B2/ja active Active
- 2017-02-24 KR KR1020170024766A patent/KR102025417B1/ko active IP Right Grant
- 2017-02-24 US US16/069,486 patent/US11096967B2/en active Active
- 2017-02-24 RU RU2018124640A patent/RU2727900C2/ru active
- 2017-02-24 EP EP17756875.5A patent/EP3388514B1/en active Active
- 2017-02-24 WO PCT/KR2017/002096 patent/WO2017146538A1/ko active Application Filing
- 2017-02-24 CN CN201780009667.XA patent/CN108699524B/zh active Active
- 2017-02-24 AU AU2017224499A patent/AU2017224499B2/en active Active
- 2017-02-24 SG SG10201912046VA patent/SG10201912046VA/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2727900C2 (ru) | 2020-07-24 |
EP3388514B1 (en) | 2023-10-25 |
EP3388514A1 (en) | 2018-10-17 |
KR102025417B1 (ko) | 2019-09-25 |
KR20170101147A (ko) | 2017-09-05 |
US20190022144A1 (en) | 2019-01-24 |
US11096967B2 (en) | 2021-08-24 |
EP3388514A4 (en) | 2018-10-24 |
AU2017224499B2 (en) | 2020-10-08 |
SG11201805468RA (en) | 2018-07-30 |
RU2018124640A3 (ja) | 2020-01-09 |
JP2019501183A (ja) | 2019-01-17 |
AU2017224499A1 (en) | 2018-07-26 |
CN108699524B (zh) | 2019-12-10 |
SG10201912046VA (en) | 2020-02-27 |
WO2017146538A1 (ko) | 2017-08-31 |
RU2018124640A (ru) | 2020-01-09 |
CN108699524A (zh) | 2018-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7223055B2 (ja) | 癌治療のための併用免疫療法及びサイトカイン制御療法 | |
JP6858128B2 (ja) | 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ | |
US20230293681A1 (en) | Antagonism of the VIP Signaling Pathway | |
ES2769778T3 (es) | Composiciones inmunomoduladoras | |
US7553661B2 (en) | Stromal antigen-presenting cells and use thereof | |
US9018006B2 (en) | Stable Tregs and related materials and methods | |
JP6580791B2 (ja) | 調節t細胞媒介性疾患の予防または治療用薬学的組成物 | |
US20210147801A1 (en) | Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/- tregs | |
AU2012259470A1 (en) | Antagonism of the VIP signaling pathway | |
KR20110125495A (ko) | Pias3을 유효성분으로 포함하는 암 또는 면역질환의 예방 또는 치료용 조성물 | |
van der Zouwen et al. | Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180705 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180705 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20180705 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20181106 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190304 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190402 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190617 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190802 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190828 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6580791 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |